DUBLIN–(BUSINESS WIRE)–The “Placenta Growth Factor – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This latest report provides comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 6, 6, 4 and 5 respectively.
This report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Central Retinal Vein Occlusion, Choroidal Neovascularization, Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Corneal Neovascularization, Metastatic Colorectal Cancer, Myopia, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Retinal Vein Occlusion, Retinopathy, Retinopathy Of Prematurity and Uveal Melanoma.
This report also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope of the report:
-
The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor.
- The report reviews PGF targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in PGF targeted therapeutics and enlists all their major and minor projects
- The report assesses PGF targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to PGF targeted therapeutics
Key report benefits:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
-
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Topics Covered:
- Placenta Growth Factor – Overview
- Placenta Growth Factor – Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Placenta Growth Factor – Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Placenta Growth Factor – Companies Involved in Therapeutics Development
- Placenta Growth Factor – Drug Profiles
- aflibercept – Drug Profile
- aflibercept biosimilar – Drug Profile
- conbercept – Drug Profile
- KH-906 – Drug Profile
- SL-186 – Drug Profile
- SL-188 – Drug Profile
- ziv-aflibercept – Drug Profile
- ziv-aflibercept biosimilar – Drug Profile
- Placenta Growth Factor – Dormant Products
- Placenta Growth Factor – Discontinued Products
- Placenta Growth Factor – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
Companies Mentioned
- Alteogen Inc
- Amgen Inc
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Cinnagen Co
- Clover Biopharmaceuticals
- Coherus BioSciences Inc
- Formycon AG
- Gene Techno Science Co Ltd
- Huons Global Co Ltd
- i2 Pharmaceuticals Inc
- Lupin Ltd
- Luye Pharma Group Ltd
- Momenta Pharmaceuticals Inc
- PharmAbcine Inc
- Regeneron Pharmaceuticals Inc
- Samsung Bioepis Co Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5wtdw5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900